Management ChangeApr 23, 2026, 04:51 PM
Vaxart Appoints James B. Breitmeyer to Board of Directors
AI Summary
Vaxart, Inc. announced the appointment of James B. Breitmeyer, M.D., Ph.D., to its Board of Directors, effective April 23, 2026. Dr. Breitmeyer is a veteran biotech executive, currently serving as CEO of Altay Therapeutics, Inc. and previously as President and CEO of Oncternal Therapeutics. His extensive experience in drug development and operational strategy is expected to enhance the Board's capabilities.
Key Highlights
- James B. Breitmeyer, M.D., Ph.D. appointed to Board of Directors.
- Appointment effective immediately on April 23, 2026.
- Dr. Breitmeyer currently serves as CEO of Altay Therapeutics, Inc.
- Previously served as President and CEO of Oncternal Therapeutics from 2016-2025.
- Board determined Dr. Breitmeyer meets independence standards.
Price Impact
More from VXRT